Cure My Disease

Don't miss your cure!

 Log in / Sign up

New antibody drug targets Hard-to-Treat cancers in early trial

NCT ID NCT06402201

Recruiting now Disease control Sponsor: CDR-Life AG Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests a new drug called CDR404 in up to 42 adults with advanced solid tumors that have a specific marker (MAGE-A4) and tissue type (HLA-A*02:01). The drug is designed to help the body's immune T-cells find and attack cancer cells. The main goals are to check safety, find the right dose, and see if the drug can shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
CDR404 (a bispecific antibody that engages T-cells to attack cancer cells)
What this could lead to
If it works, this could point toward a new treatment option for certain hard-to-treat solid tumors that express the MAGE-A4 protein.
What could go wrong
This is a very early, first-in-human trial with only 42 participants, so safety and effectiveness are not yet known. The treatment may cause side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SELECT ADVANCED SOLID TUMORS

Contacts and locations

Locations

  • Cliniques Universitaires Saint-Luc, UCL Ouvain

    RECRUITING

    Brussels, 1200, Belgium

  • Hospital 12 de Octubre

    RECRUITING

    Madrid, 28041, Spain

  • Hospital Universitari Vall d'Hebron

    RECRUITING

    Barcelona, 08035, Spain

  • Hospital Universitari i Politecnic La Fe

    RECRUITING

    Valencia, 46026, Spain

  • Institut Catala d'Oncologia, L'Hospitalet de Llobregat (ICO)

    RECRUITING

    Barcelona, 08908, Spain

  • Institut Jules Bordet

    RECRUITING

    Brussels, 1070, Belgium

  • Instituto de Investigacion Sanitaria (INCLIVA)

    RECRUITING

    Valencia, 46026, Spain

  • Isituto Europeo di Oncologia (IEO)

    RECRUITING

    Milan, 20141, Italy

  • Istituto Clinico Humanitas

    RECRUITING

    Milan, 20089, Italy

  • Pennsylvania Hospital

    RECRUITING

    Philadelphia, Pennsylvania, 19106, United States

  • Providence Cancer Institute

    RECRUITING

    Portland, Oregon, 97213, United States

    Contact Email: •••••@•••••

  • Rigshospitalet

    RECRUITING

    Copenhagen, DK-2100, Denmark

  • Royal Marsden Hospital

    RECRUITING

    Sutton, London, SM2 5PT, United Kingdom

  • START Madrid

    RECRUITING

    Madrid, 28050, Spain

  • Universitair Ziekenhuis Antwerpen

    RECRUITING

    Antwerp, 2650, Belgium

    Contact Email: •••••@•••••

  • Universitair Ziekenhuis Gent

    RECRUITING

    Ghent, 9000, Belgium

  • University of Miami

    RECRUITING

    Miami, Florida, 33136, United States

  • University of Michigan

    RECRUITING

    Ann Arbor, Michigan, 48109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.